Welcome to our dedicated page for MEDICINOVA SEC filings (Ticker: MNOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MEDICINOVA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MEDICINOVA's regulatory disclosures and financial reporting.
MediciNova, Inc. (MNOV) has elected to terminate its Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville). The agreement, originally dated July 30, 2025, had allowed MediciNova, on a discretionary basis, to issue and sell up to $30.0 million of common stock to Yorkville. Under this facility, the company sold a total of 175,000 shares at prices between $1.39 and $1.40 per share, receiving aggregate proceeds of $0.2 million. The termination, made via a formal Notice of Termination dated August 31, 2026, will become effective on September 8, 2026. At termination, there were no outstanding borrowings, advance notices, or shares remaining to be issued under the agreement, and no fees are payable by either MediciNova or Yorkville in connection with ending the facility.
MediciNova, Inc. (MNOV) entered into new executive employment agreements with President & CEO Yuichi Iwaki and Chief Medical Officer Kazuko Matsuda, replacing their prior arrangements. The agreements set base salaries, bonus opportunities, and detailed severance protections tied to both ordinary terminations and Change in Control events.
Dr. Iwaki’s package includes a higher cash-and-equity severance multiple than in non‑Change in Control cases, while Dr. Matsuda’s agreement provides somewhat lower but similar protections. Both receive COBRA coverage for specified periods and 100% acceleration of unvested equity upon qualifying terminations in connection with a Change in Control. The agreements are at-will, governed by Delaware law, and include non‑solicitation, Section 280G cutback, and Section 409A compliance provisions.
MediciNova, Inc. reported Q2 2026 revenue of $458,439, all from research services supporting an ALS study for Mayo Foundation. For the first six months of 2026, revenue was $645,423. Net loss narrowed to $2.3 million in Q2 and $4.9 million year-to-date.
Research, development and patents expense declined to $1.0 million in Q2 and $2.3 million for the first half, mainly from lower MN‑166 and MN‑001 clinical costs, while general and administrative expenses rose to $1.8 million in Q2 and $3.4 million year-to-date due to higher professional fees and stock-based compensation.
Cash and cash equivalents were $25.4 million at June 30, 2026, with working capital of $23.0 million. Management states this is sufficient to fund operations at least through November 2027, though the company expects continued losses as it advances MN‑166 and MN‑001 and may seek additional equity financing under existing shelf arrangements.
MediciNova Inc. director Nagao Hideki received a grant of 44,500 stock options for Common Stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. Following this grant, Nagao holds 44,500 stock options directly.
The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the company. This is a compensation-related award rather than an open-market purchase or sale.
MediciNova Inc. director Nicole Lemerond received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. They vest in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, contingent on her continued service with the company.
MediciNova Inc. director Carolyn Beaver received a stock option grant covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. The award vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, subject to her continued service with the company. After this grant, she holds 44,500 derivative securities (options). This is a compensation-related award rather than an open-market share purchase or sale.
MediciNova, Inc. reported results from its 2026 annual meeting of stockholders held on June 23, 2026. As of the April 24, 2026 record date, the company had 49,221,246 shares of common stock outstanding, and 29,774,819 shares were represented in person or by proxy, establishing a quorum.
Two director nominees, Hikedi Nagao and Nicole Lemerond, each received more votes "For" than "Against," with substantial broker non-votes recorded. Three additional proposals also showed more "For" than "Against" votes, based on totals of 26,697,794 vs. 1,911,245; 22,156,922 vs. 6,432,457; and 22,656,038 vs. 5,805,893, respectively.
MediciNova reported another operating loss for the quarter ended March 31, 2026 as it continues to invest in its pipeline. Revenue was $186,984, up from zero a year earlier, reflecting services under its Mayo ALS research agreement. Operating expenses were $3.0 million, slightly lower than $3.2 million in 2025 as research, development and patent costs declined to $1.3 million while general and administrative expenses rose to $1.6 million.
Net loss narrowed to $2.6 million, or $0.05 per share, compared with a $2.9 million loss, or $0.06 per share, a year earlier. Cash and cash equivalents were $27.3 million at March 31, 2026, down from $36.6 million a year ago, after $3.5 million of operating cash outflows in the quarter.
Management continues to focus on developing MN-166 (ibudilast) for several neurological indications and MN-001 (tipelukast) for fibrotic and metabolic diseases. The company reports working capital of $25.1 million and believes its current cash resources can fund operations at least through May 2027.
MediciNova, Inc. has called its 2026 Annual Meeting for June 23, 2026 in La Jolla, California. Stockholders will vote on electing two Class I directors, ratifying BDO USA, P.C. as auditor, and approving a major increase in authorized common stock.
The company proposes amending its Restated Certificate of Incorporation to raise authorized common shares from 100,000,000 to 247,000,000, while keeping preferred stock at 3,000,000 shares. As of April 24, 2026, 49,221,246 common shares were outstanding, with additional shares reserved for equity plans.